# Castle Creek Biosciences Science

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/castle-creek-biosciences-science

- Industry: Pharmaceuticals
- Headquarters: Exton, US
- Website: www.castlecreekbio.com
- Total disclosed funding: $126M
- Latest round: Series C (Mar 25, 2020)
- Investors on record: 3

## About

Castle Creek Biosciences, Inc. specializes in developing advanced cell and gene therapies for genetic diseases, aiming to significantly improve patients' lives through innovative treatment solutions.Castle Creek Biosciences, Inc. was founded in 2015 and is headquartered in Exton, US. The company focuses on creating gene therapies for genetic disorders. Jeffrey Aronin is the founder, who has a background in building healthcare companies. The firm has engaged in a total of 6 deals, with the most recent deal occurring on April 19, 2022, during which it raised USD 112.783 mn in a Series D funding round, bringing the total amount raised to USD 112.783 mn. The current company valuation stands at USD 4040.411 mn.Castle Creek Biosciences, Inc. is dedicated to developing innovative cell and gene therapies that tackle unmet medical needs in genetic diseases. Its primary offerings are advanced gene therapies aimed at treating Dystrophic Epidermolysis Bullosa (DEB) and various other debilitating genetic disorders. These therapies work to correct or compensate for genetic defects, thereby enhancing patients' quality of life. The company targets healthcare providers, hospitals, and specialized clinics across North America and Europe, with its products currently in various stages of clinical development as it seeks to broaden its treatment options for patients globally.Castle Creek Biosciences generates revenue through partnerships and collaborations with healthcare organizations, research institutions, and pharmaceutical companies. Its B2B relationships with hospitals and clinics are essential, as these establishments utilize its gene therapies. Revenue is derived from sales of these specialized therapies, established through purchasing agreements or service contracts with healthcare providers, reflecting extensive investment in research and development. The company's therapies cater to a niche market of patients with rare genetic conditions, which informs its revenue generation strategy focused on targeted outreach and clinical partnerships.In April 2022, Castle Creek Biosciences raised USD 112.783 mn in venture funding to advance its novel gene therapies and expand its pipeline. The company plans to develop and launch new gene therapy products to better serve patients with genetic disorders. Furthermore, Castle Creek aims to expand its presence in additional markets, with specific focus on regions in North America and Europe, by the end of 2023. This funding will be instrumental in supporting these initiatives and facilitating the growth of their treatment offerings.

## Funding rounds

- Series C, Mar 25, 2020, $55M — Valor Equity Partners, Fidelity Investments, Paragon Biosciences LLC
- Series B, Oct 19, 2018, $72M — Valor Equity Partners, Fidelity Investments

## Investors

- Valor Equity Partners (https://capitalatlas.ai/funds/valor-equity-partners) — Series B, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B, Series C
- Paragon Biosciences LLC — Series C